scholarly journals Dopamine-receptor blocking agent-associated akathisia: a summary of current understanding and proposal for a rational approach to treatment

2020 ◽  
Vol 10 ◽  
pp. 204512532093757
Author(s):  
Shaina Musco ◽  
Vivian McAllister ◽  
Ian Caudle
Keyword(s):  
Dopamine Receptor ◽  
Blocking Agent ◽  
Population Based ◽  
Rational Approach ◽  
Receptor Blocking ◽  
Serotonergic Receptors ◽  
Vulnerable Patient ◽  
The Subject ◽  
Dopamine Signaling ◽  
The Brain

Dopamine-receptor blocking agent-associated akathisia (DRBA-A) is an adverse effect that can significantly limit the use of these important medications for the treatment of a variety of psychiatric diseases, yet there is no unifying theory regarding its pathophysiology. This knowledge gap limits clinicians’ ability to effectively manage DRBA-A and mitigate negative outcomes in an already vulnerable patient population. Based on a review of the current literature on the subject, it is hypothesized that dopaminergic and noradrenergic signaling is perturbed in DRBA-A. Accordingly, it is proposed that the optimal agent to manage this extrapyramidal symptom should increase dopamine signaling in the affected areas of the brain and counteract compensatory noradrenergic signaling via antagonism of adrenergic or serotonergic receptors.

Hyperprolactinaemia and DNA synthesis in the pituitary gland of the rat

1983 ◽  
Vol 97 (1) ◽  
pp. 65-74 ◽  
Author(s):  
J. A. Burdman ◽  
M. T. Calabrese ◽  
R. M. MacLeod
Keyword(s):  
Dna Synthesis ◽  
Pituitary Gland ◽  
Dopamine Receptor ◽  
Dna Content ◽  
Anterior Pituitary ◽  
Blocking Agent ◽  
Anterior Pituitary Gland ◽  
Host Animal ◽  
Receptor Blocking ◽  
Tumour Bearing

Hyperprolactinaemia produced in rats by the transplanted prolactin-secreting tumours MtTW15 and 7315a significantly (P<0·01) inhibited by 70% the incorporation of [3H]thymidine into the pituitary DNA of the host animals. The weight and the DNA content of the glands were significantly (P<0·01) reduced by 30%. The administration of haloperidol, a dopamine receptor blocking agent, to the tumour-bearing rats increased the suppressed DNA replication in the anterior pituitary glands by approximately 560% in the MtTW15-bearing rat and by 100% in the 7315a-bearing animals. Furthermore, injection of drugs which stimulate prolactin release either by blocking the synthesis of dopamine (α-methyl-p-tyrosine) or the re-uptake of dopamine (reserpine) stimulated DNA synthesis by 800 and 100% respectively in the anterior pituitary gland of rats bearing the MtTW15 tumour. In contrast, lisuride, a dopamine agonist, significantly inhibited the incorporation of [3H]thymidine into the DNA of the pituitary gland of normal but not hyperprolactinaemic rats. Chronically administered oestrogens to hyperprolactinaemic rats increased the weight (100%), DNA content (31%), incorporation of [3H]thymidine into DNA (680%) and synthesis and release of prolactin (300%) in the pituitary gland. The incorporation of [3H]thymidine into tumour DNA was several times higher than in the pituitary gland of the host animal and was not significantly modified by any of the above treatments. Likewise the hyperprolactinaemia of the tumour-bearing rats was not significantly changed. In conclusion, we have shown that hyperprolactinaemia inhibits DNA synthesis in the anterior pituitary gland and this inhibition can be reversed completely by a dopamine receptor blocking agent and by hypothalamic dopamine depleting drugs. We propose that dopamine regulates, either directly or indirectly, DNA synthesis in the lactotrophs of the pituitary gland, which may be responsive to negative feedback mechanisms.

Pulsatile Growth Hormone and Prolactin: Effects of (+) Butaclamol, a Dopamine Receptor Blocking Agent

Endocrinology ◽  
1977 ◽  
Vol 101 (4) ◽  
pp. 1298-1303 ◽  
Author(s):  
J. O. WILLOUGHBY ◽  
P. BRAZEAU ◽  
J. B. MARTIN
Keyword(s):  
Growth Hormone ◽  
Dopamine Receptor ◽  
Blocking Agent ◽  
Receptor Blocking

scholarly journals Mechanism of dopamine binding and allosteric modulation of the human D1 dopamine receptor

2021 ◽  
Author(s):  
Youwen Zhuang ◽  
Brian Krumm ◽  
Huibing Zhang ◽  
X. Edward Zhou ◽  
Yue Wang ◽  
...  
Keyword(s):  
Dopamine Receptor ◽  
G Protein Coupled Receptors ◽  
Development Effort ◽  
Positive Allosteric Modulator ◽  
Neuropsychiatric Diseases ◽  
The Subject ◽  
Dopamine Signaling ◽  
Subtype Selective ◽  
G Protein Coupled ◽  
Dopaminergic Pathways

AbstractDopamine is an essential neurotransmitter, which functions are mediated by five G protein-coupled receptors, dopamine D1 to D5 receptors (D1R-D5R) in mammals. Among them, D1R is the most abundantly expressed dopamine receptor in the CNS and is the central receptor mediating excitatory dopamine signaling in multiple dopaminergic pathways. Dysregulation of D1R signaling has been directly linked to Parkinson’s disease (PD), schizophrenia, and drug abuse. Due to its fundamental functions in human diseases, D1R has long been the subject of intensive drug development effort toward the treatment of neuropsychiatric diseases. Here, we report the structures of D1R-Gs complex bound to endogenous agonist dopamine and synthetic agonist SKF81297, both with positive allosteric modulator LY3154207. These structures reveal the basis of dopamine recognition, the binding and potential allosteric regulation of DRD1 PAM LY3154207, and provide structural templates for design of subtype-selective D1R ligand for drug discovery targeting DRD1 for treating various CNS diseases.

scholarly journals Preventing Broodiness in Turkey Hens with a Dopamine Receptor Blocking Agent

1980 ◽  
Vol 59 (5) ◽  
pp. 1126-1131 ◽  
Author(s):  
J.R. MILLAM ◽  
W.H. BURKE ◽  
M.E. El HALAWANI ◽  
L.A. OGREN
Keyword(s):  
Dopamine Receptor ◽  
Blocking Agent ◽  
Receptor Blocking
Sign in / Sign up

Export Citation Format

Share Document